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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) has become a worldwide problem, although its
prevalence varies considerably among countries. The epidemiology of MRSA is now changing;
infections are no longer confined to the hospital setting, but also appear in healthy community-dwelling
individuals without established risk factors for the acquisition of MRSA. Reported prevalence rates of
community-acquired MRSA (CA-MRSA) vary widely among studies—largely because of the different
definitions employed and different settings in which the studies have been performed. At present,
molecular epidemiological definitions, based on staphylococcal cassette chromosome mec (SCCmec)
typing and phylogenetic analyses of the MRSA isolates, are considered the most reliable means by which
to distinguish between hospital-acquired MRSA (HA-MRSA) and CA-MRSA. CA-MRSA has been
isolated predominantly from skin and soft tissue infections, such as abscesses, cellulitis, folliculitis and
impetigo. Although CA-MRSA infections are usually mild, they may also be severe, and can result in
hospitalisation and even death. CA-MRSA strains differ from the major pandemic clones of MRSA that
account for the majority of epidemic HA-MRSA strains. Differences are found in SCCmec types, bacterial
growth rate, and the distribution of antibiotic resistance genes and toxin genes. Mathematical models
have shown that CA-MRSA has a high potential to become endemic in the community, and this will
impact significantly on the control of MRSA in the hospital setting. Well-designed, community-based
studies with adequate risk factor analysis are required to further elucidate the epidemiology of
CA-MRSA and to improve strategies to control MRSA in both the community and hospital settings.
Keywords Community-acquired methicillin-resistant Staphylococcus aureus, epidemiology, hospital-ac-
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
has traditionally been considered a healthcare-
associated pathogen in patients with established
risk factors [1–3]. More recently, however, MRSA
infections have been described in community-
dwelling patients without established risk factors
for the acquisition of MRSA [4–15]. The emer-
gence of this community-acquired MRSA (CA-
MRSA) as a clinically significant pathogen
necessitates reconsideration of current empirical
treatment with b-lactam antibiotics for commu-
nity-acquired S. aureus infections and current
control strategies for MRSA in hospitals. The
objective of this article is to summarise the current
knowledge concerning CA-MRSA that is relevant
to the development of future infection control
strategies.
MECHANISM OF RESISTANCE
MRSA strains harbour the mecA gene, which
encodes the low-affinity penicillin-binding pro-
tein 2a (PBP2a). The production of PBP2a confers
resistance to otherwise inhibitory concentrations
of all b-lactam antibiotics. The mecA gene is
carried on a mobile genetic element, the staphylo-
coccal cassette chromosome mec (SCCmec), which
is integrated in the chromosome of S. aureus.
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Phylogenetic analyses of international collections
of MRSA and methicillin-susceptible S. aureus
isolates have revealed that methicillin resistance
has emerged in five phylogenetically distinct
lineages, and on multiple occasions within a
given phylogenetic lineage [16]. Up to now, five
types of SCCmec have been identified, which
differ in size and genetic composition. Notably,
SCCmec type IV has been found in twice as many
clones as any other SCCmec type, and it is this
SCCmec type that is most commonly found in
clones from patients with CA-MRSA infections
[16].
DEFINITIONS
Several definitions for CA-MRSA infections have
been proposed [17]. Epidemiological definitions
have commonly been based on the timing of
isolation of MRSA in relation to the time of
admission to the hospital (that is, MRSA isolates
were classified as community-acquired if they
were cultured within the first 48–72 h of hospi-
talisation or in a community setting) [17,18].
However, colonisation with S. aureus (both meth-
icillin-susceptible S. aureus and MRSA) can per-
sist for months to years [19,20], and is
asymptomatic in the majority of individuals.
Consequently, clinical infections may develop in
a setting different from that in which the organ-
ism was initially acquired [21]. A meta-analysis of
studies reporting the prevalence of CA-MRSA
indicated that at least 85% of hospitalised patients
who met the time-based definition for CA-MRSA
infection, and 47.5% of healthy community mem-
bers found to be colonised with MRSA, had at
least one healthcare-associated risk factor for
acquisition [17]. This suggests that at least some
of the isolates were healthcare-acquired, and that
the use of time-based definitions may lead to
overestimation of the true prevalence of MRSA
originating in the community. Therefore, others
have classified MRSA infections as community-
acquired only if no healthcare-associated risk
factors were identified [7,12,22,23]. Healthcare-
associated risk factors include recent hospitalisa-
tion or surgery, dialysis, residence in a long-term
care facility, and the presence of a permanent
indwelling catheter or percutaneous medical
device at the time of culture [6,14].
However, discounting the possible community
origin of MRSA infections in patients with health-
care-associated risk factors may lead to an under-
estimation of the true prevalence of CA-MRSA, as
patients with prior healthcare exposure may be at
increased risk of colonisation and infection by a
true community-dwelling pathogen (e.g., due to
outpatient antibiotic use, immunosuppression, or
long-term intravenous access) [24]. Moreover, CA-
MRSA isolates have recently been reported to
have spread into hospitals, causing nosocomial
infections [21,24,25]. Definitions based on epide-
miological information are therefore insufficient
to distinguish between CA-MRSA and hospital-
acquired MRSA (HA-MRSA). The use of antibiotic
resistance profiles in discriminating between CA-
MRSA and HA-MRSA can also be questioned;
although antibiotic resistance in CA-MRSA iso-
lates is often limited to b-lactam antibiotics,
multidrug resistance has been reported [26].
At present, molecular epidemiological defini-
tions, based on SCCmec typing and phylogenetic
analyses, are considered the most reliable.
According to these definitions, an MRSA strain
is classified as community-acquired if the SCCmec
type IV (or V) is present and if it is phylogenet-
ically unrelated to previously known HA-MRSA
clonal lineages [16].
EPIDEMIOLOGY
MRSAhas become aworldwideproblem, although
its prevalence varies considerably among coun-
tries. Consistently high prevalence rates are found
in the USA, South America, Japan and southern
Europe, whereas prevalence rates are low in
Scandinavia, The Netherlands and Switzerland
[27–29]. Several investigators have suggested that
the epidemiology of MRSA is changing, as infec-
tions are increasingly reported in healthy commu-
nity-dwelling individuals without healthcare-
associated risk factors for the acquisition of MRSA
[4,7,17,24,30]. Clusters and outbreaks of these so-
called CA-MRSA infections have been described in
more-or-less ‘closed populations’, such as native
Americans [5], men who have sex with men [10],
prison inmates [10,31,32], children attending child-
care centres [9], military recruits [33], and compet-
itive sports participants [10,11,34]. Moreover, CA-
MRSA has now been introduced from its site of
origin in the community into the hospital setting
[24,25,35,36]. At some hospitals, CA-MRSA strains
are even displacing classic hospital-acquired
strains of MRSA [21].
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Reported prevalence rates of CA-MRSA vary
widely among studies, in part because of the use
of different definitions to distinguish between
CA-MRSA and HA-MRSA, but also because of
the different settings in which studies have been
performed. It should be noted that relatively few
studies have been conducted among randomly
selected healthy members of the community.
Most studies have been based on hospitalised
patients, or patients upon admission to the hos-
pital, which has probably resulted in an overes-
timation of the ‘true’ prevalence of CA-MRSA.
A meta-analysis of studies reporting prevalence
rates of CA-MRSA has recently been conducted
[17]. The pooled prevalence of CA-MRSA among
MRSA isolates from hospitalised patients was
30.2% in 27 retrospective studies and 37.3% in
five prospective studies. Among community
members without healthcare contacts, the pooled
MRSA colonisation rate was 0.2%. European data
are limited: the prevalence of MRSA nasal car-
riage was found to be 0.7% in a Portuguese
surveillance study among young and healthy
individuals from the community [37]; the preval-
ence of CA-MRSA upon admission to the hospital
has been reported to be 0.1% in Switzerland [38],
and 0.03% in The Netherlands [39].
Data concerning potential risk factors for the
acquisition of CA-MRSA are limited. CA-MRSA-
infected patients have been found to be younger
than patients with HA-MRSA infections [12,13].
However, this finding may well reflect the fact
that hospitalised patients represent a selected
group of older individuals. Previous exposure to
antimicrobial agents has been associated with an
increased risk for CA-MRSA infections in some
studies [15,40], but not in others [38].
CLINICAL SPECTRUM OF DISEASE
The spectrum of clinical infections caused by
CA-MRSA is similar to that caused by methicillin-
susceptible S. aureus [5,7], but clearly distinct
from that caused by HA-MRSA. Whereas
HA-MRSA commonly causes bloodstream infec-
tions and infections of the urinary and respiratory
tracts, CA-MRSA has predominantly been isola-
ted from skin and soft tissue infections, such as
abscesses, cellulitis, folliculitis and impetigo
[5,6,10–12,14]. Although CA-MRSA infections
are commonly mild, they may also be severe,
and can result in hospitalisation and ⁄ or death [4].
For example, necrotising fasciitis caused by CA-
MRSA has recently been reported as an emerging
clinical entity [41]. In addition to skin and soft
tissue infections, severe necrotising pneumonia
due to CA-MRSA has occasionally been described
in young patients without known healthcare-
associated risk factors for the acquisition of MRSA
[14]. The observed clinical spectrum of infections
caused by CA-MRSA has been associated with the
presence of Panton–Valentine leukocidin genes,
which code for the production of cytotoxins that
cause tissue necrosis and leukocyte destruction
[13,42–44]. However, other exotoxin genes or
combinations of genes could also be important
pathogenic factors [13].
GENOTYPIC AND PHENOTYPIC
CHARACTERISTICS
CA-MRSA strains differ from the major pandemic
clones of MRSA that account for the majority of
epidemic HA-MRSA strains [22,45,46]. Differ-
ences are found in SCCmec types, the presence
of additional antibiotic resistance genes, bacterial
growth rate and the distribution of toxin genes
(Table 1).
Recent studies have indicated that well-defined
CA-MRSA strains carry SCCmec type IV or V
[22,45,47], whereas the majority of HA-MRSA
strains carry SCCmec type I, II or III [48,49].
SCCmec types IV and V are relatively small in
size; for SCCmec type IV, this appears to have
resulted in its increased mobility and therefore
greater potential for horizontal spread to diverse
S. aureus genetic backgrounds, compared with
other SCCmec types [16,22,45,50–53].
In contrast to the multidrug resistance that is
usually seen in HA-MRSA strains, antibiotic
resistance in CA-MRSA strains is often limited
to b-lactam antibiotics [5,14,54]. This is consistent
with the absence of antibiotic resistance genes
other than mecA in SCCmec types IV and V, as
compared to the accumulation of multiple addi-
tional antibiotic resistance genes in SCCmec types
II and III [22,45,47,48].
CA-MRSA strains carrying SCCmec type IV
have been reported to have a higher growth rate
than HA-MRSA strains [22], which may have
enhanced the ecologic fitness of CA-MRSA.
Several studies have indicated that the presence
of Panton–Valentine leukocidin genes is common
among CA-MRSA strains from different genetic
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backgrounds, whereas these genes are rare among
HA-MRSA strains [13,43,46].
THREATS AND PREVENTION
The future impact of the emergence of CA-MRSA
on the occurrence of MRSA infections in both the
community and hospital settings is of great
interest. Some authors predict that MRSA will
become the most prevalent type of S. aureus in the
near future, and that this will mirror the emer-
gence of penicillin resistance in S. aureus in the
1950s and 1960s (Fig. 1) [30]. Dissemination of
penicillin-resistant strains from the hospital set-
ting into the community occurred at a time when
the rate of penicillin resistance among hospital
patients with staphylococcal disease approached
50%. This is comparable to the current rate of
methicillin resistance among hospitalised patients
with staphylococcal infections in US hospitals
[29]. However, contrary to the view that the
majority of CA-MRSA isolates result from the
spread of hospital-acquired strains into the com-
munity, it appears that community-based strains
are migrating into the hospital setting
[21,24,25,35,36], and that MRSA in the community
is independent of a hospital reservoir.
Mathematical models have been used to predict
the future epidemiology of MRSA and to deter-
mine effective control strategies. With the use of
such models, it has been shown that the presence
of a community reservoir has a major impact on
the control of MRSA in the hospital [55–57]. In
open communities, it will take years or even
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Fig. 1. Prevalence of penicillin resistance among Staphylococcus aureus in hospitals and in the community, 1940–1974. The
prevalence of S. aureus strains resistant to penicillin within hospitals rose dramatically in the 1940s and 1950s. However,
penicillin-resistant community-acquired strains of S. aureus were not reported until 1949, when the rate of penicillin
resistance in hospitals approached 50%. The prevalence of penicillin-resistant S. aureus in communities continued to
increase throughout the ensuing 20 years, finally approaching the resistance rates seen among hospital strains. Adapted
from Chambers [30] and Salgado [17].
Table 1. Characteristics of staphylococcal cassette chromosome mec (SCCmec) types I–V [13,22,45–48]
SCCmec Staphylococcus aureus carrying specified SCCmec type
Type Size (kb)
Presence of other
antibiotic resistance genes
Origin of
isolates
Mean doubling
time (min)
Presence of
PVL genes
I 34 No Hospital 36 Infrequent
II 53 Yes Hospital 32 Infrequent
III 67 Yes Hospital 42 Infrequent
IV 21–24 No Community 28 Frequent
V 28 No Community Unknown Unknown
PVL, Panton–Valentine leukocidin.
12 Clinical Microbiology and Infection, Volume 12 Supplement 1, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 1), 9–15
decades to see substantial reductions in the
frequency of antibiotic resistance solely as a result
of more prudent (reduced) use of antibiotics [57].
Furthermore, isolation of infected patients and
contact tracing will be hardly effective within the
community setting, because of the high frequency
of transmission by asymptomatic colonised indi-
viduals [56]. Therefore, CA-MRSA has a high
potential to become endemic in the community
unless additional control measures are intro-
duced, e.g., screening of asymptomatic individu-
als. Conversely, in the hospital setting, the
frequency of resistance may be reduced substan-
tially by restricting the input of resistant bacteria
through the implementation of appropriate infec-
tion control and other measures [57].
CONCLUSION
Although our understanding of CA-MRSA is
increasing, well-designed community-based stud-
ies with adequate risk factor analysis are
required to further elucidate the epidemiology of
CA-MRSA and to improve strategies to control
MRSA in both the community and hospital setting.
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